Adalimumab biosimilar (Coherus BioSciences)

阿达木单抗生物类似药 (Coherus BioSciences)

Report date: 2025/09/01 20:01:25

Base Information

Drug NameAdalimumab biosimilar (Coherus BioSciences)
Drug Alias NameAdalimumab-AQVH阿达木单抗生物仿制药 (Coherus BioSciences)YusimryCHS-1420
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisCrohn Disease +[8] 
Global Approved IndicationsPlaque psoriasisCrohn DiseaseColitis, Ulcerative +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2021/12/17
Country/TerritoryBulgariaCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCoherus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCoherus Biosciences IncNanjing King-Friend Biochemical Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisCrohn Disease +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A